ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 360 filers reported holding ROYALTY PHARMA PLC in Q4 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,204,515 | -15.4% | 197,365 | -2.6% | 0.01% | -18.8% |
| Q1 2024 | $6,152,446 | -38.0% | 202,583 | -42.6% | 0.02% | -38.5% |
| Q4 2023 | $9,918,270 | +61.2% | 353,089 | +55.8% | 0.03% | +44.4% |
| Q3 2023 | $6,151,362 | +428.0% | 226,653 | +498.0% | 0.02% | +500.0% |
| Q2 2023 | $1,165,015 | -52.7% | 37,899 | -44.6% | 0.00% | -57.1% |
| Q1 2023 | $2,464,884 | -2.9% | 68,412 | +6.5% | 0.01% | -12.5% |
| Q4 2022 | $2,538,132 | +25.1% | 64,224 | +27.2% | 0.01% | +33.3% |
| Q3 2022 | $2,029,000 | +88.4% | 50,487 | +97.0% | 0.01% | +100.0% |
| Q2 2022 | $1,077,000 | +48.6% | 25,623 | +37.8% | 0.00% | +50.0% |
| Q1 2022 | $725,000 | +1088.5% | 18,600 | +1228.6% | 0.00% | – |
| Q1 2021 | $61,000 | -97.0% | 1,400 | -96.6% | 0.00% | -100.0% |
| Q4 2020 | $2,042,000 | – | 40,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $263,446,000 | 59.92% |
| Memorial Sloan Kettering Cancer Center | 1,128,255 | $43,957,000 | 50.90% |
| Vantage Consulting Group Inc | 2,727,854 | $106,277,000 | 41.47% |
| Indie Asset Partners, LLC | 756,874 | $29,488,000 | 22.15% |
| Overbrook Management Corp | 723,250 | $28,178,000 | 6.25% |
| Brown University | 621,759 | $24,224,000 | 5.93% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $8,527,000 | 3.82% |
| Lagoda Investment Management, L.P. | 141,560 | $5,515,000 | 2.97% |
| Greytown Advisors Inc. | 131,143 | $5,109,000 | 2.47% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,025,610 | $78,918,000 | 2.41% |